公开(公告)号：EP2640725A1

公开(公告)日：2013-09-25

申请号：EP11793604.7

申请日：2011-11-18

申请人： Incyte Corporation

发明人： RODGERS, James, D. ,  ZHU, Wenyu ,  GLENN, Joseph

IPC分类号： C07D487/04

CPC分类号： C07D487/04

摘要： The present invention provides heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines of Formula I: wherein X, Y, Z, L, A, R
5 , n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP2640723A1

公开(公告)日：2013-09-25

申请号：EP11791155.2

申请日：2011-11-18

申请人： Incyte Corporation

发明人： RODGERS, James D. ,  ZHU, Wenyu ,  SHAO, Lixin ,  GLENN, Joseph ,  SHEPARD, Stacey

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/519

CPC分类号： C07D487/04 ,  C07D471/04

摘要： The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R
5 , n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

摘要翻译： 本发明提供式I的环丁基取代的吡咯并嘧啶和吡咯并吡啶：其中X，Y，Z，L，A，R 5，n和m如上定义，以及它们的组合物和使用方法， 激酶（JAK）并且可用于治疗与JAK活性相关的疾病，所述JAK包括例如炎性疾病，自身免疫疾病，癌症和其他疾病。

公开(公告)号：EP4321513A2

公开(公告)日：2024-02-14

申请号：EP23202364.8

申请日：2017-03-27

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  WANG, Xiaozhao ,  BARBOSA, Joseph ,  BURNS, David M. ,  FENG, Hao ,  GLENN, Joseph ,  HE, Chunhong ,  HUANG, Taisheng ,  MEI, Song ,  ZHUO, Jincong

IPC分类号： C07D403/14

摘要： This application relates to compounds of Formula I:

or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

公开(公告)号：EP2917221A1

公开(公告)日：2015-09-16

申请号：EP13789679.1

申请日：2013-10-31

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHU, Wenyu ,  MEI, Song ,  GLENN, Joseph

IPC分类号： C07D495/12 ,  A61K31/4365 ,  A61K31/437 ,  A61P37/00

CPC分类号： C07D495/14 ,  A61K31/437 ,  C07D495/12

摘要： The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP2751109A1

公开(公告)日：2014-07-09

申请号：EP12775861.3

申请日：2012-08-31

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  YAO, Wenqing ,  COMBS, Andrew, P. ,  YUE, Eddy, W. ,  MEI, Song ,  ZHU, Wenyu ,  GLENN, Joseph ,  MADUSKUIE, Thomas, P., Jr. ,  SPARKS, Richard, B. ,  DOUTY, Brent ,  HE, Chunhong

IPC分类号： C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P29/00 ,  A61P27/00 ,  A61P19/00 ,  A61P1/00 ,  A61P17/00

CPC分类号： A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00

摘要： The present invention provides heterocyclylamine derivatives of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

摘要翻译： 本发明提供式（I）的杂环胺衍生物：其中变量在本文中定义，其调节磷酸肌醇3-激酶（PI3K）的活性并且可用于治疗与PI3K活性相关的疾病，包括例如， 炎性疾病，基于免疫的疾病，癌症和其他疾病。

公开(公告)号：EP1763351A2

公开(公告)日：2007-03-21

申请号：EP05790938.4

申请日：2005-06-27

申请人： INCYTE CORPORATION

发明人： XUE, Chu-Biao ,  ZHENG, Changsheng ,  FENG, Hao ,  XIA, Michael ,  GLENN, Joseph ,  CAO, Ganfeng ,  METCALF, Brian, W.

IPC分类号： A61K31/497 ,  A61K31/445 ,  A61K31/44 ,  C07D403/14 ,  C07D241/04 ,  C07D401/10

CPC分类号： C07D405/14 ,  C07D309/14 ,  C07D405/12

摘要： The present invention is directed to compounds of Formula (I): which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

公开(公告)号：EP1746997A2

公开(公告)日：2007-01-31

申请号：EP05780063.3

申请日：2005-05-10

申请人： INCYTE CORPORATION

发明人： XUE, Chu-Biao ,  ZHENG, Changsheng ,  CAO, Ganfeng ,  FENG, Hao ,  XIA, Michael ,  ANAND, Rajan ,  GLENN, Joseph ,  METCALF, Brian

IPC分类号： A61K31/4745 ,  C07D217/00

CPC分类号： C07D471/04 ,  C07D217/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12

摘要： The present invention is directed to compounds of Formula (I) which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

公开(公告)号：EP4321513A3

公开(公告)日：2024-05-08

申请号：EP23202364.8

申请日：2017-03-27

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  WANG, Xiaozhao ,  BARBOSA, Joseph ,  BURNS, David M. ,  FENG, Hao ,  GLENN, Joseph ,  HE, Chunhong ,  HUANG, Taisheng ,  MEI, Song ,  ZHUO, Jincong

IPC分类号： C07D487/04 ,  A61P35/00 ,  A61K31/519 ,  C07D403/04

CPC分类号： A61K31/53 ,  C07D403/04 ,  C07D403/14 ,  A61P35/00 ,  C07D487/04

摘要： This application relates to compounds of Formula I:

or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

公开(公告)号：EP2640725B1

公开(公告)日：2015-01-07

申请号：EP11793604.7

申请日：2011-11-18

申请人： Incyte Corporation

发明人： RODGERS, James, D. ,  ZHU, Wenyu ,  GLENN, Joseph

IPC分类号： C07D487/04

CPC分类号： C07D487/04

公开(公告)号：EP1734966B1

公开(公告)日：2013-07-31

申请号：EP05755295.2

申请日：2005-04-12

申请人： Incyte Corporation

发明人： XUE, Chu-Biao ,  CAO, Ganfeng ,  Huang, Taisheng ,  CHEN, Lihua ,  ZHANG, Ke ,  WANG, Anlai ,  MELONI, David ,  ANAND, Rajan ,  GLENN, Joseph ,  METCALF, Brian

IPC分类号： A61K31/495 ,  C07D401/06 ,  A61P31/00

CPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/502 ,  A61K31/506 ,  A61K45/06 ,  C07D401/06 ,  C07D417/14 ,  C07D471/04 ,  A61K2300/00

摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.